H. Lundbeck (DB:LDBB) - Stock Price, News & Analysis

LDBB Stock Overview

LDBB fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	5/6
Dividends	3/6

Rewards

Trading at 64% below our estimate of its fair value

Earnings are forecast to grow 9.89% per year

Earnings grew by 19.5% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Unstable dividend track record

H. Lundbeck A/S Competitors

Dermapharm Holding

XTRA:DMP

€1.7b

Merck KGaA

XTRA:MRK

€66.0b

PharmaSGP Holding

XTRA:PSG

€266.4m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Price	kr.3.75
52 Week High	kr.5.08
52 Week Low	kr.3.67
Beta	0
1 Month Change	-1.26%
3 Month Change	-7.82%
1 Year Change	-17.44%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-13.08%

Recent updates

Shareholder Returns

	LDBB	DE Pharmaceuticals	DE Market
7D	-0.3%	1.9%	1.2%
1Y	-17.4%	-28.2%	2.0%

Return vs Industry: LDBB exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.

Return vs Market: LDBB underperformed the German Market which returned 2% over the past year.

Price Volatility

Is LDBB's price volatile compared to industry and market?
LDBB volatility
LDBB Average Weekly Movement	3.2%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: LDBB has not had significant price volatility in the past 3 months.

Volatility Over Time: LDBB's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1915	5,681	Charl van Zyl	www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.

H. Lundbeck A/S Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
LDBB fundamental statistics
Market cap	€4.25b
Earnings (TTM)	€307.15m
Revenue (TTM)	€2.67b

14.3x

P/E Ratio

1.6x

P/S Ratio

Is LDBB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LDBB income statement (TTM)
Revenue	kr.19.91b
Cost of Revenue	kr.4.49b
Gross Profit	kr.15.43b
Other Expenses	kr.13.14b
Earnings	kr.2.29b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 15, 2024

Earnings per share (EPS)	2.31
Gross Margin	77.48%
Net Profit Margin	11.50%
Debt/Equity Ratio	16.8%

How did LDBB perform over the long term?

See historical performance and comparison

Dividends

2.1%

Current Dividend Yield

30%

Payout Ratio

LDBB Stock Overview

Rewards

Risk Analysis

H. Lundbeck A/S Competitors

XTRA:DMP

€1.7b

XTRA:MRK

€66.0b

XTRA:PSG

€266.4m

DB:2FJ0

€92.8m

Price History & Performance

Recent News & Updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

Recent updates

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Full year 2023 earnings released

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

Third quarter 2023 earnings released

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Second quarter 2023 earnings released: EPS: kr.0.60 (vs kr.0.51 in 2Q 2022)

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

First quarter 2023 earnings released: EPS: kr.0.89 (vs kr.0.41 in 1Q 2022)

Full year 2022 earnings released

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

Less than half of directors are independent

Third quarter 2022 earnings released

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

Second quarter 2022 earnings released: EPS: kr.0.51 (vs kr.1.90 in 2Q 2021)

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti